You
are here: Home: Meet
The Professors Vol. 1 2003: Case
1
|
• |
A mother in her early 30s
with two young children |
• |
1.7-cm infiltrating ductal
carcinoma (ER-negative, PR-negative, HER2-positive [FISH]) |
• |
Lumpectomy and AND (7/9
positive nodes) and radiation therapy |
• |
Received AC x 4, paclitaxel
x 4 |
• |
Became pregnant 4 months
post-treatment |
• |
Developed right arm/shoulder
pain and numbness in hand 1 month later |
• |
Exam: Supraclavicular fullness |
• |
MRI: 4 x 4 cm right supraclavicular
mass involving the brachial plexus |
• |
FNA and open biopsy: Negative
for tumor |
• |
Pain increased, developed
shortness of breath |
• |
At 25 weeks gestation, right
pleural effusion was discovered; fluid was positive for adenocarcinoma |
|
Key discussion points: |
|
|
Defining the goals of therapy
for a pregnant patient with metastatic disease |
|
Risks and benefits of systemic
therapy for metastatic disease in pregnancy |
|
Effects of pregnancy on breast
cancer progression |
|
Emotional impact of practice
on the oncologist |
|
Dr
Love: Dr Harth, would you describe your
discussions with this woman and her family in terms of their
expectations and goals for therapy and for the future?
Dr Harth: The
extent of the disease was not determined until she was at 25 weeks
gestation, and she wanted to be aggressive with therapy and try
to live as long as possible. Her family was very dependent on her.
The main question was: What therapies could we offer?
Dr Love: How
did you discuss the potential effects of therapy on the fetus?
Dr Harth: I told her we were
unsure of the impact many chemotherapy agents could have on the
fetus. In addition, we discussed the fact that we didn’t
know whether she would respond to treatment. She had a very aggressive
tumor, which relapsed within a short period of time after adjuvant
therapy.
Dr Love: Dr
Seidman, how would you think through this case?
Dr Seidman: Thank
God we don’t see this situation very often. This is an incredibly
difficult case in which we’re actually considering the fates
of two lives — one confronted with metastatic breast cancer
and another that hasn’t yet begun.
This woman needs to understand that treatment is unlikely to
have any curative potential. Hopefully, this will factor into her
decision regarding the potential toxicities of therapy to which
her fetus would be exposed. Some of these concerns are probably
not as great as we might imagine, because she is well into her
second trimester; therefore, most organ system formation has already
occurred.
I would consider trastuzumab, because this agent doesn’t
have the classic toxicities of chemotherapy, but I do not know
whether trastuzumab crosses the placenta nor do I know its potential
toxicity to the fetus.
This patient’s disease is rapidly progressing, causing
brachial plexopathy, a malignant pleural effusion, and she still
has to go through childbirth. I would want to medically maximize
her chances of a good outcome in delivering this child. It will
take eight to twelve weeks before this woman reaches steady state
concentrations of trastuzumab; therefore, in addition to trastuzumab,
I would likely add a cytotoxic agent. My bias would be to use carboplatin,
vinorelbine, or gemcitabine in combination with trastuzumab because
she recently received an anthracycline and a taxane.
Dr Tripathy: I would try very
hard to hold off on any therapy until she delivers. Apart from
the pleural effusion, which can be tapped for symptomatic relief,
I don’t think there is a pressing, life-threatening reason
to treat her. I think she should wait until delivery, which is
10 weeks away, at most.
We have ample evidence that antibodies do cross the placental
barrier, and I would suspect that trastuzumab crosses through the
placenta. The HER2 pathway is important in cardiac and neural development,
and I am concerned about using trastuzumab in pregnancy at any
stage of fetal development. I am postulating all of this, but I
don’t think we can exclude harm.
I would let her deliver and then institute palliative chemotherapy.
At that point, your choices are much greater, and I would certainly
use trastuzumab-based therapy.
Dr Love: Debu,
what would it take for you to give her chemotherapy? For example,
how would you deal with the situation if two weeks later her pleural
effusion was becoming worse, she had mediastinal lymph nodes, and
her pain was increasing?
Dr Tripathy: I
would probably use induction chemotherapy with an anthracycline
and cyclophosphamide. These chemotherapy agents are not optimal
because she has already received them, but there is data from MD
Anderson looking at this combination as adjuvant or neoadjuvant
therapy. Fluoropyrimidines, such as capecitabine, would also be
a reasonable choice if we are up against the wall. As soon as she
delivers, I would add trastuzumab and revert to a combination like
vinorelbine/trastuzumab in a patient like this who has received
a taxane.
Dr Love: Andy,
a related issue in this case is advising premenopausal women about
becoming pregnant after having breast cancer. How do you approach
this?
Dr Seidman: Because this woman’s
risk of relapse was high, particularly in the short term, and because
she was in her early 30s, I would have urged her to wait before
conceiving. This is always a long and careful discussion, but for
a younger woman, I would strongly urge the “watch-and-wait” approach.
I don’t tell these women they can never become pregnant.
We do not have good evidence that pregnancy increases the risk
of relapse.
Dr Love: Would
you have advised her against pregnancy if she had a lower risk
of relapse, for example, if she had a smaller tumor with negative
nodes?
Dr Seidman: Because of her
young age, I still would have taken a “watch-and-wait” approach.
Her fertility in her late 30s would still probably be quite acceptable,
and I would like for there to be some “water under the bridge” so
to speak.
Next page
Page 1 of 2
|